PREPARE TO PROVIDE YOUR RECOMMENDATION.
TAKE THE INFLUENZA VACCINE CHALLENGE.

Before administration, please see the Prescribing Information for Flublok® Quadrivalent.

This activity is sponsored by VaxServe®, Inc.


Welcome to the INFLUENZA VACCINE CHALLENGE. As a pharmacist, you can help identify the immunization needs of adults 50 years and older coming into the pharmacy and provide the appropriate influenza vaccine recommendation.

Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.

Your task is to watch an informational video and answer 6 questions about Flublok® Quadrivalent, an option that can be considered when an older adult comes into the pharmacy for their influenza vaccination.1,2

Answer all 6 questions correctly and print a personalized certificate recognizing your knowledge regarding Flublok® Quadrivalent and your preparedness to counsel on this option.

1

Watch the
VIDEO

2

Answer the
QUESTIONS

3

Complete the
CHALLENGE

1
As accessible health care professionals, pharmacists have an important role in identifying the immunization needs of older adults and providing the appropriate vaccine recommendation. Of every 5 adults aged 50 years and older, how many obtained their flu vaccination at the community pharmacy?
A. 2
B. 3
C. 4
D. 5
2
Flublok® Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. It is approved for use in persons aged ____?
A. 6 months and older
B. 50 years and older
C. 18 years and older
D. 65 years and older
3
True or False. In a randomized controlled efficacy clinical trial, Flublok® Quadrivalent provided better protection against influenza versus a standard-dose quadrivalent inactivated influenza vaccine due to any PCR-confirmed circulating strain in adults aged 50 and older.
A. True
B. False
4
In a study of approximately 9000 adults aged 50 years and older, Flublok® Quadrivalent (N = 4312) exhibited a similar safety profile compared with a standard-dose inactivated influenza vaccine (N = 4327).1 What were the most common (≥10%) local injection site reactions and systemic adverse reactions within 7 days of administration of Flublok® Quadrivalent ? Select ALL that apply.
A. The most common (≥10%) systemic adverse reactions were headache and fatigue.
B. The most common (≥10%) injection-site reactions were tenderness and pain.
C. The most common (≥10%) injection-site reactions were joint pain and muscle aches.
D. No adverse reactions have been reported for any vaccine.
5
Flublok® Quadrivalent is an influenza vaccine with a unique composition. Select the TRUE statements about the manufacturing of Flublok® Quadrivalent.
<p>Flublok<sup>®</sup> Quadrivalent is created the same way as standard dose influenza vaccines.</p>
<p>Flublok<sup>®</sup> Quadrivalent is made with recombinant DNA technology. This process uses the genetic code of influenza to produce recombinant hemagglutinin antigens, which eliminates the need to grow influenza virus during manufacturing—avoiding antigenic adaptions or mutations that could lead to reduced vaccine effectiveness.</p>
<p>Flublok<sup>®</sup> Quadrivalent is composed with 3X more hemagglutinin antigens versus a standard-dose quadrivalent inactivated influenza vaccine, with 45 micrograms of hemagglutinin per strain versus 15 micrograms of hemagglutinin per strain in a standard-dose influenza vaccine.</p>
<p>Flublok<sup>®</sup> Quadrivalent does <span style="font-family: NewsGothBold;">NOT</span> contain egg proteins, antibiotics, or preservatives. It comes in a 0.5 mL prefilled syringe to be given as a single dose. The single-dose, prefilled syringes contain no natural rubber latex.</p>
6
Pharmacists have an important role in providing an appropriate recommendation for influenza vaccination to eligible populations, including adults aged 50 years and older. It is important to be prepared to recommend an influenza vaccine for this age group. Consider Flublok® Quadrivalent as an option.<br /> Which of the following important educational points can be provided on potential benefits and risks of vaccination with Flublok® Quadrivalent? Select all that apply.
Flublok® Quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine.
Flublok® Quadrivalent contains no egg proteins, antibiotics, or preservatives.
Flublok® Quadrivalent was proven to provide better protection versus a standard-dose quadrivalent inactivated influenza vaccine in adults aged 50 years and older.
In a study of adults 50 years and older, Flublok® Quadrivalent exhibited a similar safety profile compared with a standard-dose inactivated influenza vaccine.
Q1.
Q2.
Q3.
Q4.
Q5.
Q6.
You must Answer all 6 questions correctly to complete the challenge

References

1. Flublok® Quadrivalent [Prescribing Information]. Meriden, CT: Protein Sciences Corporation.

2. Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017;376:2427-2436.

Prescribing Information
Welcome
Video
Q1
Q2
Q3
Q4
Q5
Q6
Complete

IMPORTANT SAFETY INFORMATION FOR FLUBLOK® QUADRIVALENT (INFLUENZA VACCINE)

Flublok Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Flublok Quadrivalent should be based on careful consideration of the potential benefits and risks.

IMPORTANT SAFETY INFORMATION FOR FLUBLOK® QUADRIVALENT (INFLUENZA VACCINE)

Flublok Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Flublok Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Flublok Quadrivalent is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Flublok Quadrivalent may not protect all recipients.

For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, and fatigue. Other adverse reactions may occur.

Before administration, please see the Prescribing Information for Flublok Quadrivalent.



MAT-US-2105501-v1.0-06/2022



© 2022 MJH Life Sciences™ and Pharmacy Times. All rights reserved.

06/2022 VAX8313